DR. LAL PATHLABS share price has zoomed 3% and is presently trading at Rs 2,913.0.
Meanwhile, the BSE HEALTHCARE index is at 37,890.8 (up 1.2%).
Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 12.7%) and Lupin (up 7.1%).
ERIS LIFESCIENCES (down 1.0%) and SUVEN PHARMACEUTICALS (down 1.0%) are among the top losers today.
Over the last one year, DR. LAL PATHLABS has moved up from Rs 2,252.6 to Rs 2,913.0, registering a gain of Rs 660.4 (up 29.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,627.6 to 37,890.8, registering a gain of 47.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 96.8%), Cadila Healthcare (up 96.6%) and Lupin (up 95.7%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,166.1 (up 0.2%).
The top gainers among the BSE Sensex today are HCl Tech. (up 3.5%) and ICICI Bank (up 2.2%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.
In the meantime, NSE Nifty is at 24,340.1 (up 0.2%). HCl Tech. and ICICI Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,205.1 to 80,166.1, registering a gain of 14,961.1 points (up 22.9%).
DR. LAL PATHLABS net profit grew 50.8% YoY to Rs 858 million for the quarter ended March 2024, compared to a profit of Rs 569 million a year ago. Net sales rose 11.1% to Rs 5,454 million during the period as against Rs 4,910 million in January-March 2023.
For the year ended March 2024, DR. LAL PATHLABS reported 50.3% increase in net profit to Rs 3,623 million compared to net profit of Rs 2,411 million during FY23. Revenue of the company grew 10.4% to Rs 22,266 million during FY24.
The current Price to earnings ratio of DR. LAL PATHLABS, based on rolling 12 month earnings, stands at 67.1.
Equitymaster requests your view! Post a comment on "DR. LAL PATHLABS Gains 3%; BSE HEALTHCARE Index Up 1.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!